-
Featured Authors
-
Archives
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Monthly Archives: August 2012
2012 BIO Investor Forum: Looking Ahead to Investment Opportunities
The biggest biotech news out of Washington in recent months was the Jumpstart Our Business Startups (JOBS) Act, which passed Congress overwhelmingly and was signed into law by President Obama in April. For those not familiar, the JOBS Act creates a new category of issuers, called “emerging growth companies” (EGCs), which is defined as newly public companies with than $1 billion in annual revenues and a public float below $700 million. EGCs are given a Read More >
MJFF’s Innovative, New Funding Program Addresses the Entire Therapeutic Pipeline
To date, the Michael J. Fox Foundation for Parkinson’s Research has funded over $297 million in research, $77 million of which has been awarded to more than 160 unique, industry-led projects. In June 2012, MJFF announced its newest funding mechanism, the Therapeutic Pipeline Program (TPP), which combines MJFF’s previous Therapeutics Development Initiative (TDI), Repositioning Drugs for PD, and Clinical Intervention Awards (CIA) programs into a single, streamlined funding opportunity. Open to both industry and academic Read More >
Spotlight on India’s Emerging Biotech Sector
India’s biotechnology sector is a burgeoning one, with more than 325 companies and some with revenues in the billions of dollars. According to the BioSpectrum-ABLE (Association of Biotechnology Led Enterprises) Biotech Industry Survey of 2011, the industry has grown by 21.5% in 2006-2011, surging to $4 billion. Furthermore, India is the world’s largest manufacturer of vaccines and the growth of India vaccine makers arises from their ability to develop and produce high-quality vaccines with low Read More >
Indices, IPOs, Approvals – YTD Update Aug 14th, 2012
We are now more than eight months into the year and biotech indices have maintained their outperformance, squeezed out a modest size IPO class, and delivered double digit novel FDA approvals. 1. Indices. The Nasdaq Biotech Index (NBI) is up 27% Year to Date (YTD) as of last Friday. It was up nearly 20% by the end of the 1st quarter, consolidated during the 2nd quarter, and has participated in the summer rally to tack on another 7%. Here Read More >
Psoriasis Awareness Month: Psoriasis isn’t contagious but awareness is!
Each August, the National Psoriasis Foundation (NPF) sponsors Psoriasis Awareness Month, dedicated to raising awareness, educating the public and dispelling myths about the disease. What is psoriasis? Psoriasis isn’t contagious, but awareness is. Learn more at www.psoriasis.org. Photo © National Psoriasis Foundation 2012. Psoriasis is a chronic, noncontagious, genetic autoimmune disease that appears on the skin in red, scaly patches that itch, crack and bleed. It is the most common autoimmune disease in the country, Read More >
